Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

被引：0
|
作者：
Powles, T. [1 ]
Motzer, R. J. [2 ]
George, D. J. [3 ]
Jonasch, E. [4 ]
Pal, S. [5 ]
Tannir, N. M. [4 ]
Signoretti, S. [6 ]
Mai, T. H. [7 ]
Scheffold, C. [8 ]
Wang, E. [9 ]
Aftab, D. T. [10 ]
Escudier, B. [11 ]
Choueiri, T. K. [12 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[5] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
[6] Brigham & Womens Hosp, Pathol, 75 Francis St, Boston, MA 02115 USA
[7] Ann Arbor Pharmacometr Grp, Pharmacometr, Ann Arbor, MI USA
[8] Exelixis Inc, Clin Dev, San Francisco, CA USA
[9] Exelixis Inc, Translat Med, San Francisco, CA USA
[10] Exelixis Inc, Execut Adm, San Francisco, CA USA
[11] Gustave Roussy, Med Oncol, Villejuif, France
[12] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
872P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve in patients (pts) with advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Mainwaring, Paul
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
    Escudier, Bernard J.
    Powles, Thomas
    Motzer, Robert J.
    Olencki, Thomas
    Aren, Osvaldo Rudy
    Oudard, Stephane
    Bracarda, Sergio
    Tomczak, Piotr
    Castellano, Daniel E.
    Appleman, Leonard Joseph
    Drabkin, Harry A.
    Vaena, Daniel A.
    Milwee, Steven
    Youkstetter, Jillian
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
    Powles, T. B.
    Escudier, B.
    de Souza, P.
    Chowdhury, S.
    Pook, D.
    Harmenberg, U.
    Basappa, N.
    Geynisman, D.
    Merchan, J.
    Redman, B. G.
    Ryan, C.
    Goodman, O.
    Ho, T.
    Singh, P.
    Lougheed, J.
    Patel, M.
    Knox, J. J.
    Motzer, R. J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 109 - 109
  • [25] Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
    Denize, Thomas
    Farah, Subrina
    Cimadamore, Alessia
    Flaifel, Abdallah
    Walton, Emily
    Sticco-Ivins, Maura A.
    Labaki, Chris
    Braun, David A.
    Sun, Maxine
    Wang, Evelyn
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 748 - 755
  • [26] Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Tannir, N.
    Powles, T.
    Motzer, R. J.
    Rolland, F.
    Gravis, G.
    Staehler, M.
    Rink, M.
    Retz, M.
    Csoszi, T.
    McCaffrey, J.
    De Giorgi, U.
    Caserta, C.
    Cheporov, S.
    Esteban Gonzalez, E.
    Duran, I.
    Larkin, J. G.
    Berg, W.
    Clary, D.
    Escudier, B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
    Cella, David
    Escudier, Bernard
    Tannir, Nizar M.
    Powles, Thomas
    Donskov, Frede
    Peltola, Katriina
    Schmidinger, Manuela
    Heng, Daniel Y. C.
    Mainwaring, Paul N.
    Hammers, Hans J.
    Lee, Jae Lyun
    Roth, Bruce J.
    Marteau, Florence
    Williams, Paul
    Baer, John
    Mangeshkar, Milan
    Scheffold, Christian
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 757 - +
  • [28] Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
    Bracarda, S.
    Choueiri, T. K.
    Powles, T.
    Motzer, R. J.
    Olencki, T.
    Frontera, O. A.
    Oudard, S.
    Rolland, F.
    Tomczak, P.
    Castellano, D.
    Appleman, L.
    Drabkin, H.
    Vaena, D.
    Milwee, S.
    Youkstetter, J.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S196 - S196
  • [29] Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Tannir, Nizar M.
    Powles, Thomas
    Motzer, Robert J.
    Rolland, Frederic
    Gravis, Gwanaelle
    Staehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Cheporov, Sergey
    Gonzalez, Emilio Esteban
    Duran, Ignacio
    Larkin, James G.
    Berg, William
    Clary, Douglas O.
    Escudier, Bernard
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 129 - 130
  • [30] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
12345